JANX
Janux Therapeutics, Inc.
Latest Form 4:Sale$57KbyDoyle Janeen Noel (Chief Corp. & Bus. Dev. Ofcr) · filed Jun 5, 2026
Janux Therapeutics, Inc. (JANX) has 22 SEC Form 4 filings (32 transaction rows) in the rolling window, disclosed by 7 distinct insiders. Most recent filing: Aug 1, 2026.
The most active filer is Chief Business Officer Meyer Andrew Hollman with 4 filings.
- Industry:Biotechnology
- CEO:David Alan Campbell
- Employees:108
- HQ:San Diego, CA, US
- IPO:2021-06-11
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$1.1M
reported sales (SEC code S)
Unique Insiders
7
in the rolling window
Market Cap
$1.1B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
Doyle Janeen NoelFirst filing | Chief Corp. & Bus. Dev. Ofcr | Sale | 4,059 | $57K | Jun 5 | SEC ↗ |
Dobek MariaFirst in 4 months | Vice President, Accounting | Sale | 2,038 | $29K | May 13 | SEC ↗ |
DiRaimondo ThomasFirst filing | Chief Scientific Officer | Sale | 2,505 | $34K | Jan 2 | SEC ↗ |
Winter Charles M.First filing | Chief Technical Officer | Sale | 2,401 | $33K | Jan 2 | SEC ↗ |
McIver ZachariahFirst filing | Chief Medical Officer | Sale | 2,714 | $37K | Jan 2 | SEC ↗ |
Campbell David AlanFirst filing | President and CEO | Sale | 8,072 | $111K | Jan 2 | SEC ↗ |
Dobek MariaFirst filing | Vice President, Accounting | Sale | 1,462 | $20K | Jan 2 | SEC ↗ |
| Chief Business Officer | Sale | 1,879 | $26K | Jan 2 | SEC ↗ | |
| Chief Business Officer | Sale | 3,333 | $110K | Dec 3 | SEC ↗ | |
| Chief Business Officer | Sale | 3,333 | $100K | Nov 14 | SEC ↗ | |
Meyer Andrew HollmanFirst filing | Chief Business Officer | Sale | 16,665 | $501K | Oct 30 | SEC ↗ |
Related companies
Janux Therapeutics, Inc. is in the Healthcare sector.